An experimental injection just shrank the dangerous fat wrapped around human organs by 12% in a real clinical trial, while patients on a placebo saw that same fat grow.
Quick Take
- An early human trial found CBL-514 injections cut visceral fat by 12.01%, measured with MRI scans.
- Patients given a placebo saw their visceral fat increase by 5.68% over the same period.
- CBL-514 already has published Phase 2 data showing it shrinks abdominal subcutaneous fat too.
- Longer studies are still needed to prove the fat loss lasts and actually improves health.
What The Injection Trial Actually Found
Researchers gave participants injections of CBL-514 in the lower abdomen every three weeks, for up to 12 weeks, with doses as high as 600 milligrams. Four weeks after the last shot, MRI scans showed visceral fat dropped 12.01% on average in the treatment group. The placebo group’s visceral fat rose 5.68% instead, according to Fox News reporting on the Phase 2 trial results.
Visceral fat is the kind that matters most for health. It wraps around the liver, kidneys and intestines deep inside the belly, unlike the fat you can pinch under the skin. Doctors have long linked high visceral fat to heart disease, diabetes and other metabolic problems, which is exactly why a drug that targets it is drawing attention far beyond the cosmetic world.
Separate Trial Already Proved It Shrinks Belly Fat You Can Pinch
CBL-514 is not brand new to science. A published, randomized, placebo-controlled Phase 2 study already showed it works on subcutaneous fat, the layer under the skin. That trial randomized 76 people and found the drug group lost significantly more abdominal fat than the placebo group, with results that were statistically convincing at both four and eight weeks.
That earlier study used a 2-to-1 design, meaning twice as many people got the real drug as got the placebo. The fat-volume gap between the two groups measured in the hundreds of milliliters, a difference unlikely to happen by chance. It gave CBL-514 its first solid human evidence before the newer visceral-fat numbers made headlines.
Why This Compound Is Being Watched Beyond The Trial Site
Caliway Biopharmaceuticals sponsors the clinical trials testing CBL-514, and the company has registered multiple studies on ClinicalTrials.gov covering subcutaneous fat, cellulite and pharmacokinetics in healthy volunteers. Sponsor involvement in a trial is normal in drug development, but it also means outside researchers and regulators will want to see the full data before drawing final conclusions about how well the drug works.
Outside research backs up why visceral fat reduction matters in the first place. Large lifestyle studies have found that a 10% drop in visceral fat is tied to better insulin resistance scores, and one analysis linked similar reductions to a 28% lower risk of developing type 2 diabetes. That context helps explain why a 12% reduction from an injection, rather than months of diet and exercise, is generating so much buzz among doctors and patients alike.
NEW TREATMENT: An experimental injection called CBL-514 slashed dangerous visceral fat — the deep abdominal fat wrapped around internal organs — by 12% in early human trials, while patients on a placebo saw their visceral fat increase nearly 6%.
The drug works by selectively… pic.twitter.com/23PMe6LG62
— Fox News Health (@foxnewshealth) October 12, 2026
Still, the visceral-fat measurement came from a secondary report rather than a full peer-reviewed paper dedicated to that specific result. The published Phase 2 study’s main focus was subcutaneous fat, not the fat around organs. Readers should know this is early-stage evidence, not a finished product sitting on pharmacy shelves, and longer trials will need to confirm how long the fat reduction lasts.
For now, the facts stand on their own merit. A controlled human trial measured real organ-surrounding fat with MRI technology, compared it against a placebo group, and found a meaningful gap favoring the drug. That is a legitimate scientific result, built on the kind of randomized design conservatives rightly demand before trusting any new medical claim, and it deserves recognition without the hype machine running ahead of the data.
Sources:
clinicaltrials.gov, pmc.ncbi.nlm.nih.gov, academic.oup.com, cdn.clinicaltrials.gov, clareohealth.com
